A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group

20250 citationsJournal Articlegreen Open Access

Authors

Katherine A. Janeway · Dana-Farber Cancer Institute

Alexander J. Chou · Cornell University

Allen Buxton · Children's Oncology Group

Joel M. Reid · Cancer Clinic

Michael S. Isakoff · Connecticut Children's Medical Center

Lisa M. Kopp · University of Arizona

Pooja Hingorani ·

Abstract

Denosumab was well-tolerated with anticipated side effects and pharmacokinetic and pharmacodynamic parameters but had insufficient activity for further development in osteosarcoma.

Topics & Keywords

Bone Metabolism and Diseases Bone Tumor Diagnosis and Treatments Bone health and treatments

Publication Details

Published in: Clinical Cancer Research

Volume 32, Issue 1, pp. 36-44

DOI: 10.1158/1078-0432.ccr-24-2885

Field-Weighted Citation Impact: 0.00

Command Palette

A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group

Authors

Abstract

Topics & Keywords

Publication Details